3.1.9. matching donors recipients. histocompatibility antigens show remarkable polymorphism human leukocyte antigen (hla) matching still important kidney transplantation transplant outcome correlates number hla mismatches [231-234]. human leukocyte antigen incompatibility result proliferation activation recipient’s cd4+ cd8+ t-cells concomitant activation b-cell allo-antibody production. may lead cellular humoral graft rejection. matching concentrate hla antigens, impact outcome. human leukocyte antigens a, b, c well dr must determined potential recipients donors according current guidelines national allocation rules [231-236]. additionally, recommended determine hla-dq antigens donor recipient. furthermore, hla-dp antigen characterisation may performed, especially sensitised recipients [231-236]. patients registered renal transplantation must serum screened anti-hla antibodies, particularly common pregnancy, previous transplant, transplant rejection, blood transfusions [231-236]. thorough pre-transplant testing hla antibodies must performed according current recommendations [231-236]. sera potential organ recipients screened hla-specific antibodies every three months stipulated national and/or international organ exchange organisations [231-236]. addition, screening hla-specific antibodies carried two four weeks every immunising event, e.g. blood transfusion, transplantation, pregnancy, graft explantation [231-236]. highly sensitised patients prioritised access special allocation programmes , acceptable mismatch (am) programme eurotransplant . careful analysis hla antibody specificities must carried avoid unacceptable hla antigens determine acceptable hla antigens potential donors, expected give negative cross-match result. definition unacceptable hla antigens implemented according local allocation rules international recommendations [231-235,238]. information unacceptable hla antigens highlighted patient’s details database national kidney-sharing programme, preventing unnecessary transport kidneys recipients high antibody sensitivity. avoid hyper-acute rejection (har), adequate (e.g. cdc, virtual) cross-match tests must performed kidney combined kidney/pancreas transplantation accordance national international recommendations [231-234,236]. laboratories provide hla-testing, hla antibody testing cross-matching transplant centres must valid accreditation ensure accuracy reliability [225,226,231-233]. must follow standards national international organisations, european federation immunogenetics . previously, compatibility abo blood group antigens hla antigens critical importance kidney transplantation. may change future, e.g. new u.s. allocation system a2 a2b donors transplanted b recipients . avoid increasing imbalance demand supply deceased donor kidney transplantation recipients, abo identity demanded several organ allocation organisations exceptions, e.g. zero hla-a+b+dr-mismatch kidneys . introduction antibody elimination methods, potent immunosuppression novel agents (e.g. anti b-cell drugs), successful abo-incompatible living donor transplantations, good long-term outcomes possible . however, higher costs infection rates described. even barrier positive cross-match due preformed hla antibodies discussion newer “desensitisation” techniques available cases available living donors . success rates lower, antibody-mediated rejections frequent, survival may better compared waiting list survival dialysis. rapidly evolving field, research needed define standard protocols. “desensitisation” protocols experimental patients undergoing “desensitisation” treated specialised centres, outcomes documented. patients informed adequately risks limitations alternative strategies (e.g. acceptable mismatch programmes, cross-over transplantation donor chains) discussed. summary evidencelehuman leukocyte antigen matching important kidney transplantation transplant outcome correlates number hla mismatches. matching concentrate hla antigens, impact outcome.3in accordance national international recommendations adequate (e.g. cdc, virtual) cross-match tests must performed kidney combined kidney/pancreas transplantation avoid hyper-acute rejection.3 recommendationsstrength ratingdetermine abo blood group human leukocyte antigen a, b, c dr phenotypes candidates awaiting kidney transplantation.strongtest donor recipient human leukocyte antigen dq. human leukocyte antigen dp testing may performed sensitised patients.strongperform thorough testing hla antibodies transplantation.strongperform adequate cross-match tests avoid hyper-acute rejection, kidney combined kidney/pancreas transplantation.strong